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In this preliminary screening study for developing potent analgesic and anti-inflammatory compounds,
eight new 4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide derivatives were synthesized and screened for
their analgesic and anti-inflammatory activities as well as gastric ulceration potential in tested animals.
Their structures were elucidated by their IR, 1 H-NMR and elemental analysis. All of the compounds
exhibited high analgesic and anti-inflammatory activities. None of the compounds except compound 2g
caused gastric lesions or bleeding in tested animals.
Key Words: 2-Oxo-3H-benzoxazole, butanamide, analgesic, anti-inflammatory, COX-1, COX-2.

Introduction
2-Oxo-3H-benzoxazole derivatives exhibit a broad range of biological properties1−4 including analgesic and
anti-inflammatory activity5−10. Among them, especially 3-substituted-2-oxo-3H-benzoxazoles are known to
exhibit analgesic and anti-inflammatory properties8,11 . It has also been reported that mannich bases of
6-acyl-2-oxo-3H-benzoxazoles resulted in compounds with potent analgesic activity8 . Additional studies
with some 3-aminoalkyl-2-oxo-3H-benzoxazole derivatives also demonstrated potent analgesic and antiinflammatory activity, and showed that these compounds exerted their in vivo activity by inhibiting the
synthesis of prostaglandin E72 .
For some time, our research group has been interested in studying the 2-oxo-3H-benzoxazoles for
developing analgesic and anti-inflammatory compounds, and we have shown that some (2-oxo-3H-benzoxazol3-yl)acetic acid and propanonic acid derivatives, and also some (2-oxo-3H-benzoxazol-3-yl)propanamides had
potent analgesic and anti-inflammatory activity12−15. It was also demonstrated that the 6-acyl function
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attached to the benzene portion of 2-oxo-3H-benzoxazole ring was favorable for analgesic activity in these
derivatives, and that (6-acyl-2-oxo-3H-benzoxazol-3-yl)alkanoic acids possessed potent analgesic and antiinflammatory activity with reduced gastric toxicity16. In general, most of the research on this class of
compounds included substitutions on positions 3 and 6 of the 2-oxo-3H-benzoxazole nucleus. As a result,
2-oxo-3H-benzoxazoles bearing N-alkyl, N-acyl, N-diaminoalkyl and 6-acyl substituents were reported to
have higher analgesic and anti-inflammatory activity8,9,16,17.
Therefore, these observations prompted us to prepare the amide derivatives of (5-chloro-2-oxo-3Hbenzoxazol-3-yl)butanoic acid (Figure 1) as potential analgesic and anti-inflammatory compounds.
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Figure 1.

Experimental
All chemicals were purchased from Merck Co. and Aldrich Co. by local vendors. COX Inhibitor Screening
Assay Kits (No: 560131) including recombinant ovine COX-1 and recombinant human COX-2 were obtained
from Cayman Chemical (France). Selective COX-2 inhibitor reference compound DFU (5,5-dimethyl-3-(3fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone) was obtained from Merck Research Laboratories
(USA). Melting points were determined on a electrothermal melting point apparatus and were uncorrected.
IR spectra were recorded on a Bruker Vector 22 IR (Opus Spectroscopic Software Version 2.0) spectrometer
(KBr, υ, cm−1 ). 1 H-NMR spectra were recorded on a Bruker 400 FT-NMR spectrometer using TMS as an
internal standard in DMSO-d6 . All chemical shifts were reported as δ (ppm) values. Elemental analyses
were performed with Leco-932 (C,H,N,S-O-Elemental analyzer) at the Instrumental Analysis Center of the
Scientific and Technical Research Council of Turkey (Ankara, Turkey).
Ethyl [4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)]butanoate
An equimolar amount of ethyl 4-chlorobutanoate was added to a solution of 0.001 mol sodium salt
of 5-chloro-2-oxo-3H-benzoxazole in 30 mL DMF. The mixture was heated at 80 ◦ C for 8h, then cooled
to room temperature and poured into ice-water. The precipitate formed was filtered off and recrystallized
from ethanol-water to yield 85%. mp: 42-43 ◦ C. FT-IR (KBr) cm−1 1778 (C=O ring), 1724 (C=O ester ).
1

H-NMR (DMSO-d6 ) δ 1.41 (t, 3H, -O-CH2 -CH3 ), 2.23 (m, 2H, -CH2 -CH2 -CH2 -), 2.56 (t, 2H, -CH2 -CH2 -

COO-), 4.00 (t, 2H, -N-CH2 -CH2 - ), 4.2 (q, 2H, -O-CH2 -CH3 ), 7.11-7.34 (m, 3H, 2-oxo-3H-benzoxazole-H4 ,
H6 , H7 ). Anal. (C13 H14 ClNO4 ): C,H,N calc. 55.04, 4.97, 4.94; found. 54.83, 5.16, 4.87.
4-(5-Chloro-2-oxo-3H-benzoxazol-3-yl)butanoic acid (1)
0.01 Mol ethyl [4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)]butanoate was dispersed in 30 mL concentrated
HCl (37%) and refluxed for 30 min. The mixture was cooled and filtered and the precipitate was crystallized
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from water to yield 80% . mp: 150 ◦ C. FT-IR (KBr) cm−1 : 1758 (C=O lactam), 1700 (C=O acid). 1 H-NMR
(DMSO-d6 ) δ 2.13 (m, 2H, -CH2 -CH2 -CH2 -), 2.51 (t, 2H, -CH2 -CH2 -COOH), 3.92 (t, 2H, -N-CH2 -CH2 -),
6.96-7.22 (m, 3H, 2-oxo-3H-benzoxazole-H4 , H6 , H7 ). Anal. (C11 H10 ClNO4 ): C, H, N calc. 51.68, 3.94,
5.48; found. 51.92, 3.54, 5.38.
4-(5-Chloro-2-oxo-3H-benzoxazol-3-yl)butanamide derivatives
0.012 Mol of thionyl chloride was added to the solution of 0.01 mol 4-(5-chloro-2-oxo-3H-benzoxazol3-yl)butanoic acid in dichloromethane. The solution was refluxed for 5 h and then cooled to 0 ◦ C. The
dichloromethane solution of 0.01 mol of triethylamine and 0.02 mol appropriate amine derivative was added
dropwise to the solution. After the reaction was complete, dichloromethane was evaporated to dryness,
acetone was added to the residue and the precipitate formed (triethylamine hydrochloride) was filtered off.
Acetone was evaporated and the residue was recrystallized from appropriate solvents.
N-(2-Pyridyl)-4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide (2a)
Recrystallized from ethanol to yield 60%. Mp: 102 ◦ C. FT-IR (KBr) cm−1 : 1759 (C=O ring), 1683
(C=O amide), 3241 ( N-H ). 1 H-NMR (DMSO-d6 ) δ 2.35 (m, 2H, -CH2 -CH2 -CH2 - ), 2.65 (t, 2H, -CH2 CH2 -C=O ), 4.15 (t, 2H, -N-CH2 -CH2 -), 7.2-8.4 (m, 7H, Ar-H), 8.65 (s, 1H, NH). Anal. (C16 H14 ClN3 O3 ):
C, H, N calc. 57.93, 4.25, 12.67. found. 58.30, 3.89, 12.51.
N-(5-Chloro-2-pyridyl)-4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide (2b)
Recrystallized from methanol to yield 56%. mp: 117 ◦ C. FT-IR (KBr) cm−1 : 1792 (C=O lactam),
1667 (C=O amide), 3283 ( N-H ). 1 H-NMR (DMSO-d6 ) δ 2.30 (m, 2H, -CH2 -CH2 -CH2 -), 2.74 (t, 2H, -CH2 CH2 -C=O), 4.15 (t, 2H, -N-CH2 -CH2 -), 7.07-8.5 (m, 6H, Ar-H), 8.60 (s, 1H, NH). Anal. (C16 H13 Cl2 N3 O3 ):
C, H, N calc. 52.48, 3.58, 11.47 found. 52.08, 3.83, 11.42.
N-(2,6-Dichloro-3-pyridyl)-4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide (2c) Recrystallized from 1-propanol to yield 51%. mp: 131 ◦ C. FT-IR (KBr) cm−1 : 1766 (C=O lactam), 1672 (C=O
amide), 3277 ( N-H ). 1 H-NMR (DMSO-d6 ) δ 2.30 (m, 2H, -CH2 -CH2 -CH2 -), 2.75 (t, 2H, -CH2 -CH2 -C=O),
4.15 (t, 2H, -N-CH2 -CH2 -), 7.1-8.7 (m, 5H, Ar-H), 8.93 (s, 1H, NH). Anal. (C16 H12 Cl3 N3 O3 ): C, H, N calc.
47.97, 3.02, 10.49 found. 48.37, 3.28, 10.51.
N-(3-Methyl-2-pyridyl)-4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide (2d)
Recrystallized from ethanol to yield 49%. mp: 109 ◦ C. FT-IR (KBr) cm−1 : 1772 (C=O lactam),
1670 (C=O amide), 3253 ( N-H ). 1 H-NMR (DMSO-d6 ) δ 2.2 (s, 3H, -CH3 ), 2.30 (m, 2H, -CH2 -CH2 -CH2 -),
2.80 (t, 2H, -CH2 -CH2 -C=O), 4.10 (t, 2H, -N-CH2 -CH2 -), 7.1-8.4 (m, 6H, Ar-H), 8.75 (s, 1H, NH). Anal.
(C17 H16 ClN3 O3 ): C, H, N calc. 59.05, 4.66, 12.15 found. 59.12, 4.27, 12.10.
N-(6-Methyl-2-pyridyl)-4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide (2e)
Recrystallized from ethanol-water (2:1) to yield 58%. mp: 110 ◦ C. FT-IR (KBr) cm−1 : 1762 (C=O
lactam), 1672 (C=O amide), 3275 (N-H). 1 H-NMR (DMSO-d6 ) δ 2.35 (m, 2H, -CH2 -CH2 -CH2 -), 2.43 (s,
3H, -CH3 ), 2.61 (t, 2H, -CH2 -CH2 -C=O), 4.07 (t, 2H, -N-CH2 -CH2 -), 6.9-8.2 (m, 6H, Ar-H), 8.20 (s, 1H,
NH). Anal. (C17 H16 ClN3 O3 ): C, H, N calc. 59.06, 4.66, 12.15 found. 58.65, 5.05, 11.86.
N-(4-Methyl-2-pyridyl)-4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide (2f )
Recrystallized from ethanol to yield 50%. mp: 113 ◦ C. FT-IR (KBr) cm−1 : 1765 (C=O lactam),
1681 (C=O amide), 3241 (N-H). 1 H-NMR (DMSO-d6 ) δ 2.2 (s, 3H, -CH3 ), 2.27 (m, 2H, -CH2 -CH2 -CH2 -),
2.65 (t, 2H, -CH2 -CH2 -C=O), 4.07 (t, 2H, -N-CH2 -CH2 -), 6.9-8.3 (m, 6H, Ar-H), 8.91 (s, 1H, NH). Anal.
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(C17 H16 ClN3 O3 ): C, H, N calc. 59.05, 4.66, 12.15 found. 59.44, 4.26, 12.20.
N-(4,6-Dimethyl-2-pyridyl)-4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide (2g)
Recrystallized from ethanol to yield 56%. m.p: 124 ◦ C. FT-IR (KBr) cm−1 : 1771 (C=O lactam),
1652 (C=O amide), 3515 (N-H). 1 H-NMR (DMSO-d6 ) δ 2.05 (m, 2H, -CH2 -CH2 -CH2 -), 2.23 (s, 3H, -CH3 ),
2.38 (s, 3H, -CH3 ), 2.45 (t, 2H, -CH2 -CH2 -C=O), 3.82 (t, 2H, t, -N-CH2 -CH2 -), 6.9-7.7 (m, 5H, Ar-H), 9.50
(s, 1H, NH). Anal. (C18 H18 ClN3 O3 ): C, H, N calc. 60.09, 5.04, 11.68 found. 60.41, 5.03, 11.74.
N-(Thiazol-2-yl)-4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanamide (2h)
Recrystallized from ethanol to yield 62%. mp: 147 ◦ C. FT-IR (KBr) cm−1 : 1758 (C=O lactam), 1683
(C=O amide), 3496 ( N-H ). 1 H-NMR (DMSO-d6 ) δ 2.20 (m, 2H, -CH2 -CH2 -CH2 -), 2.60 (t, 2H, -CH2 -CH2 C=O), 3.95 (t, 2H, -N-CH2 -CH2 -), 7.10-7.6 (m, 5H, Ar-H), 8.10 (s, 1H, NH). Anal. (C14 H12 ClN3 O3 S): C,
H, N calc. 49.78, 3.58, 12.44 found. 50.18, 3.62, 12.55.

Pharmacology
Male Swiss albino mice (The Animal Breeding Laboratories of the Refik Saydam Hıfzısıhha Institute, Ankara,
Turkey) weighing 20-25 g were used for all in vivo experiments. The animals were housed in colony cages (six
mice each), maintained on a standard pellet diet and water ad libitum and left for 2 days for acclimatization
before the experimental sessions. The food was withdrawn on the day before the experiment, but they were
allowed free access to water. All experiments were carried out according to the suggested ethical guidelines
for the care of laboratory animals.

Preparation of test samples for bioassay
Test samples were given orally to the test animals after suspending the samples in a mixture of distilled H2 O
and 0.5% sodium carboxymethyl cellulose (CMC). The control group animals received the same experimental
handling as those in the test groups except that the drug treatment was replaced with appropriate volumes
of the dosing vehicle. Either indomethacin (10 mg/kg) or aspirin (100 mg/kg) in 0.5% CMC was used as a
reference drug.

p-Benzoquinone-induced writhing test18
Sixty minutes after the oral administration of test samples, the mice were intraperitoneally injected with 0.1
mL/10 g body weight of 2.5% (w/v) p-benzoquinone (PBQ; Merck) solution in distilled H2 O. The control
animals received an appropriate volume of the dosing vehicle. The mice were then kept individually for
observation and the total number of abdominal contractions (writhing movements) was counted for the next
15 min, starting 5 min after the PBQ injection. The data represent the average of the total number of
writhing movements observed. Analgesic activity was expressed as the percentage change from the writhing
controls.

Carrageenan-induced hind paw edema test
The method of Kasahara et al.19 was used. The difference in footpad thickness between the right and left
foot was measured with a pair of dial thickness gauge callipers (Ozaki Co., Tokyo, Japan). The mean values
of the treated groups were compared with those of the control group and analyzed using statistical methods.
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Sixty minutes after the oral administration of the test sample or dosing vehicle, each mouse was injected
with a freshly prepared (0.5 mg/25µl) suspension of carrageenan (Sigma, St. Louis, Missouri, USA) in
physiological saline (154 mM NaCl) into the sub-plantar tissue of the right hind paw and 25 µL of saline
solution into that of the left as a secondary control. Measurements were obtained and evaluated as described
above every 90 min for 360 min.

Acute toxicity
The animals used in the carrageenan-induced paw edema experiment were observed for 24 h and mortality
was recorded for each group at the end of the observation period.

Gastric side effects
Eight hours after the analgesic activity experiment, the mice were killed under deep ether anesthesia and
their stomachs were removed. Then the abdomen of each mouse was opened through the great curvature
and examined under a dissecting microscope for lesions or bleeding.

Statistical analysis of data
Data obtained from animal experiments were expressed as the mean standard error (±SEM). Statistical
differences between the treatments and the control were tested by ANOVA. Data with P < 0.05 values were
considered significant.

COX inhibitor screening assay
The in vitro inhibitory activity of the compounds on COX-1 and COX-2 was assayed by the use of the COX
Inhibitor Screening Assay Kit including recombinant ovine COX-1 and recombinant human COX-2 isoforms
(Cayman Chemical No: 560131) according to the enzyme immunoassay (EIA) protocol recommended by
the supplier. Preliminary screening of both title compounds and references (non-selective COX inhibitor
indomethacin20 and selective COX-2 inhibitor DFU21 ) was performed at 10 µM concentration to determine
the percent inhibition on COX-1 and COX-2 isoforms. Each drug was evaluated at 10 µM concentration
in duplicate determinations. In short, the samples were incubated with recombinant COX-1 or COX-2 at
37 ◦ C with gentle shaking for 10 min, and the reaction was then stopped by the addition of 1M HCl and
submerging the tubes in a cold bath. Levels of PGE2 in the supernatants were determined by EIA.

Results and Discussion
In the synthesis of resulting amide derivatives (2a-h), commercially available 5-chloro-2-oxo-3H-benzoxazole
was used as the starting material. Ethyl 4-(5-chloro-2-oxo-3H-benzoxazol-3-yl)butanoate was prepared by
the reaction of the sodium salt of 5-chloro-2-oxo-3H-benzoxazole with ethyl 4-chlorobutanoate in DMF,
and subsequent acid hydrolysis of this compound gave its free acid (1). 4-(5-Chloro-2-oxo-3H-benzoxazol3-yl)butanoic acid was treated with thionyl chloride to prepare the corresponding acid chloride, which was
then reacted without subsequent purification with appropriate amine derivatives to obtain resulting novel
amide derivatives (2a-h). The preparation of the title amide derivatives is outlined in Scheme 1.
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In this first screening study, the analgesic activity of the eight synthesized amide derivatives was
determined by a p-benzoquinone-induced writhing test18 . As seen in Table 1, the title amide derivatives
2a-h resulted in compounds with high analgesic activities. In particular, amide derivatives having pyridine
groups with methyl substitutions (compounds 2d-g) exhibited analgesic activity higher than aspirin in the
p-benzoquinone-induced writhing test. Meanwhile, chlorine substitutions on the pyridine part (2b and 2c)
were not well tolerated and resulted in lower analgesic activity. In addition, the presence of unsubstituted
pyridine (2a) and thiazole (2h) substituents in the amide portion also caused lower analgesic activity than
aspirin, indicating that alkyl substitution(s) on the pyridine part of the molecule was favored for analgesic
activity.
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Scheme 1. Synthetic route for the synthesis of the title amide derivatives.
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The anti-inflammatory activity of the title amide derivatives was assessed a carrageenan-induced hind
paw edema model19 . Since the carrageenan edema has been used in the development of indomethacin, many
researchers have adapted this procedure for screening potential anti-inflammatory compounds. It is known
that an edema produced by carrageenan is a biphasic event, and it is reported that the inhibitory effects
of agents that act on the first stage of the carrageenan-induced hind paw inflammation are attributable to
the inhibition of the chemical mediators such as histamine, serotonin and bradykinin22,23. On the other
hand, the second stage of the edema might be related to the arachidonic acid metabolites since it is inhibited by aspirin, indomethacin and other cyclooxygenase (COX) inhibitors22,23. The anti-inflammatory
activity of the synthesized compounds also demonstrated a parallel result with their corresponding analgesic
activities in that compounds 2d-g demonstrated the highest, activity comparable to that of indomethacin.
As seen in Table 2, all compounds exhibited considerable anti-inflammatory activity during the last phase
of carrageenan-induced edema, indicating that these compounds might exert their activities through the
inhibition of COX enzymes, therefore preventing the formation of inflammatory prostaglandins from arachidonic acid. In addition, since the microscopic examination of the stomachs of tested animals showed no
gastric lesions or bleeding with any compound except 2g (in one of the six animals small gastric lesions were
observed), this also encouraged us to test the COX inhibitory activities of the title amide derivatives.
Table 1. Analgesic activity of the synthesized compounds.

Compound
Control
2a
2b
2c
2d
2e
2f
2g
2h
Aspirin
a

Number of
Writhings ± SEM
38.2 ± 4.29
18.2 ± 1.54
19.0 ± 2.27
22.3 ± 1.71
14.3 ± 1.15
10.7 ± 1.20
14.2 ± 1.60
15.0 ± 1.29
22.2 ± 1.71
16.3 ± 2.26

Analgesic
Activitya
Inhibition of
Writhing, %
52.3b
50.3b
41.6b
62.6c
71.9c
62.8c
60.7c
41.9b
57.3b

Ratio of
Gastric
Lesions
0/6
0/6
0/6
0/6
0/6
0/6
0/6
1/6
0/6
2/6

Analgesic activities of the compounds and aspirin were tested at 100 mg/kg dose as described in the Experimental

part.

b

P < 0.01

c

P < 0.001.

Based on these results, compounds 2a and d-g were considered to have potent analgesic and antiinflammatory activity at 100 mg/kg doses, and were selected for further studies to investigate their inhibitor
activities on COX enzymes by in vitro COX inhibitor screening assay. As known, cyclooxygenases exist in
two isoforms, one constitutive (COX-1), which is involved in many physiological processes including gastric
cytoprotection; and the other inducible (COX-2), which appears to play a major role in the production
of prostaglandins associated with the inflammatory process24 . After the discovery that the most currently
used non-steroidal anti-inflammatory drugs (NSAIDs) exhibit their therapeutic and side effects through
the non-selective inhibition of COX enzymes (COX-1 and COX-2), research on developing selective COX-2
inhibitors has gained a lot of attention25,26. In addition, the differential tissue distribution of COX-1 and
473

Synthesis of New 4-(5-Chloro-2-oxo-3H-benzoxazol-3-yl)butanamide ..., H. O. GÜLCAN, et al.,

COX-2 provides a rationale for the development of selective COX-2 inhibitors as anti-inflammatory and
analgesic agents that lack the GI liabilities exhibited by currently marketed NSAIDs.
Although we hypothesized that the selected compounds would have inhibitory activity on COXenzymes to shut down prostaglandin synthesis to exert their analgesic and anti-inflammatory activities, this
was not the case and none of the selected in vivo active compounds resulted in considerable inhibition at
10 µM neither in COX-2 nor in COX-1 (Table 3). Therefore, we conclude that these 4-(5-chloro-2-oxo-3Hbenzoxazol-3-yl)butanamide derivatives do not exert their analgesic or anti-inflammatory activities through
COX inhibition and that other mechanisms might be involved. The mechanism that underlies the analgesic
and anti-inflammatory activities of the resulting amide derivatives are currently under investigation in our
laboratory.
Table 2. Anti-inflammatory activity of the synthesized compounds.

Compound

2a
2b
2c
2d
2e
2f
2g
2h
Indomethacin
Control
a

90 min
33.2 ± 2.73
(12.2)
33.5 ± 1.71
(11.4)
31.3 ± 2.45
(17.2)
34.7 ± 1.59
(8.2)
34.7 ± 2.86
(8.2)
33.0 ± 3.28
(12.7)
31.0 ± 2.34
(17.9)
36.5 ± 2.59
(3.4)
26.5 ± 2.06
(29.9)d
37.8 ± 3.57

Anti-inflammatory activitya
Thickness of Edema ± SD
(Inhibition %)
180 min
270 min
36.7 ± 2.33 34.5 ± 1.20
(21.6)
(40.3)b
38.3 ± 1.65 38.5 ± 1.71
(18.2)
(33.4)b
36.8 ± 2.32 38.8 ± 3.61
(21.4)
(32.9)d
37.3 ± 2.01 40.2 ± 0.95
(20.3)
(30.4)b
34.5 ± 1.99 34.7 ± 2.40
(26.3)
(39.9)b
33.5 ± 2.26 34.2 ± 2.36
(40.8)b
(28.4)d
31.7 ± 2.63 37.0 ± 1.86
(35.9)b
(32.3)d
40.2 ± 2.98 41.0 ± 2.76
(14.1
(29.1)d
27.3 ± 1.91 27.2 ± 2.76
(41.7)b
(52.9)c
46.8 ± 5.39 57.8 ± 5.15

360 min
37.2 ± 2.47
(44.6)c
38.0 ± 1.67
(43.5)c
38.0 ± 2.92
(43.5)c
32.7 ± 1.45
(51.3)c
27.7 ± 1.43
(58.8)c
32.8 ± 1.4
(51.2)c
34.5 ± 2.55
(48.7)c
43.8 ± 4.39
(34.8)b
29.0 ± 1.07
(56.8)c
67.2 ± 3.69

Anti-inflammatory activities of the compounds and indomethacin were tested at 100 mg/kg dose and 10 mg/kg

dose, respectively, as described in the Experimental part.

b

P < 0.01

c

P < 0.001

d

P < 0.05.

Table 3. Inhibitory activity of selected active compounds on COX-1 and COX-2.

Compound
2a
2d
2e
2f
2g
Indomethacin
DFU
474

COX-1 inhibition, %
6.5
11
20
9.8
26
69
0

COX-2 inhibition, %
8.7
15
35
0
34.5
78
86
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Inhibitor activity of the selected compounds at 10 µM concentration on COX-1 and COX-2 were tested using the
COX inhibitor screening assay as described in the Experimental part. Indomethacin and DFU at 10 µM were used
as nonselective COX inhibitor and selective COX-2 inhibitor references, respectively, in the assays.
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1. S. Dalkara, Ü. Çalış and R. Sunal, J. Pharm. Belg., 43, 372-378 (1988).
2. J. F. Delhomel, S. Yous, P. Depreux and D. Lessieur, J. Heterocyclic Chem., 36, 1241-1245 (1999).
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23. R. Vinegar, W. Schreiber and R. Hugo, J. Pharmacol. Exp. Ther., 166, 96-103 (1969).
24. P. Brooks, P. Emery, J.F. Evans, H. Fenner, C.J. Hawkey, C. Patrono, J. Smolen, F. Breedveld, R. Day,
M. Dougados, E.W. Ehrich, J. Gijon-Banos, T.K. Kvien, M.H. Van Rijswijk, T. Warner and H. Zeidler,
Rheumatology, 38, 779-788 (1999).
25. G. Dannhardt and S. Laufer, Curr. Med. Chem., 7, 1101-1112 (2000).
26. J. Van Ryn, G. Trummlitz and M. Pairet, Curr. Med. Chem., 7, 1145-1161 (2000).

476

